Determinants of first- and second-generation antipsychotic drug use in clinically unstable patients with schizophrenia treated in four European countries

International Clinical Psychopharmacology

Volumn 21, Issue 2, 2006, Pages 73-79

  Barbui, Corrado ^a   Nosè, Michela ^a   Mazzi, Maria Angela ^a   Bindman, Jonathan ^b   Leese, Morven ^b   Schene, Aart ^c   Becker, Thomas ^d,e   Angermeyer, Matthias C ^d   Koeter, Maarten ^c   Gray, Richard ^b   Tansella, Michele ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e UNIVERSITY OF ULM   (Germany)

Author keywords

Epidemiology; First generation antipsychotic drugs; Polypharmacy; Schizophrenia; Second generation antipsychotic drugs

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AGE; ARTICLE; CORRELATION ANALYSIS; DEMOGRAPHY; DISEASE SEVERITY; DRUG CHOICE; DRUG EXPOSURE; DRUG USE; EUROPE; FEMALE; HUMAN; INTROSPECTION; ITEM GROUP CHECKLIST OF THE SCHEDULE FOR CLINICAL ASSESSMENT IN NEUROPSYCHIATRY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MARRIAGE; PATIENT ATTITUDE; PATIENT COMPLIANCE; POLYPHARMACY; PRIORITY JOURNAL; PSYCHOLOGIC TEST; QUALITY OF LIFE; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION; UNEMPLOYMENT; WIDOW; ADOLESCENT; AGED; ATTITUDE TO HEALTH; CLINICAL PRACTICE; DECISION MAKING; DISEASE COURSE; DRUG COMBINATION; EPIDEMIOLOGY; HOSPITALIZATION; MIDDLE AGED; STATISTICS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; ATTITUDE TO HEALTH; DECISION MAKING; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; HEALTH CARE SURVEYS; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33645226157     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yic.0000185022.48279.db     Document Type: Article

References (40)

1. Addington D, Addington J, Maticka-Tyndale E (1994). Specificity of the Calgary Depression Scale for schizophrenics. Schizophr Res 11:239-244.
2. Addington D, Addington J, Maticka-Tyndale E, Joyce J (1992). Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res 6:201-208.
3. Andretta M, Ciuna A, Corbari L, Cipriani A, Barbui C (2005). Impact of regulatory changes on first- and second-generation antipsychotic drug consumption and expenditure in Italy. Soc Psychiatry Psychiatr Epidemiol 40:72-77.
4. Baldessarini RJ, Kando JC, Centorrino F (1995). Hospital use of antipsychotic agents in 1989 and 1993: stable dosing with decreased length of stay. Am J Psychiatry 152:1038-1044.
5. Baley SL (1999). The measurement of problem drinking in young adulthood. J Stud Alcohol 60:234-244.
6. Barbui C, Danese A, Guaiana G, Mapelli L, Miele L, Monzani E, Percudani M (2002). Prescribing second-generation antipsychotics and the evolving standard of care in Italy. Pharmacopsychiatry 35:239-243.
7. Becker T, Hulsmann S, Knudsen HC, Martiny K, Amaddeo F, Herran A, et al. (2002). Provision of services for people with schizophrenia in five European regions. Soc Psychiatry Psychiatr Epidemiol 37:465-474.
8. Biggs D, De Ville B, Suen E (1991). A method of choosing multiway partitions for classification and decision trees. J Appl Stat 1:49-62.
9. Buchanan RW, Ball MP, Weiner E, Kirkpatrick P, Gold JM, McMahon RP, Carpenter WT (2005). Olanzapine treatment of residual positive and negative symptoms. Am J Psychiatry 162:124-129.
10. Centorrino F, Eakin M, Bahk WM, Kelleher JP, Goren J, Salvatore P, et al. (2002). Inpatient antipsychotic drug use in 1998, 1993, and 1989. Am J Psychiatry 159:1932-1935.
11. David AS (1990). Insight and psychosis. Br J Psychiatry 156:798-808.
12. Day JC, Wood G, Dewey M, Bentall RP (1995). A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry 166:650-653.
13. Dingemans PM, Linszen DH, Lenior ME, Smeets RM (1995). Component structure of the expanded Brief Psychiatric Rating Scale (BPRS-E). Psychopharmacology (Berl) 122:263-267.
14. Hamann J, Ruppert A, Auby P, Pugner K, Kissling W (2003). Antipsychotic prescribing patterns in Germany: a retrospective analysis using a large outpatient prescription database. Int Clin Psychopharmacol 18: 237-242.
15. Hausman J, McFadden D (1984). Specification tests for the multinomial logit model. Econometrica 52:1219-1240.
16. Hogan TP, Awad AG, Eastwood R (1983). A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 13:177-183.
17. Hotopf M, Churchill R, Lewis G (1999). Pragmatic randomised controlled trials in psychiatry. Br J Psychiatry 175:217-223.
18. Huang HC, Lin TK, Ngui PV (1993). Analysing a mental health survey by chi squared automatic interaction detection. Ann Acad Med 22:332-337.
19. Jones SH, Thornicroft G, Coffey M, Dunn G (1995). A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry 166:654-659.
20. Kapur S, Remington G (2000). Atypical antipsychotics. Patients value the lower incidence of extrapyramidal side effects. BMJ 321:1360-1361.
21. Kass GV (1980). An exploratory technique for investigating large quantities of categorical data. Appl Stat 29:119-127.
22. Kemp R, Kirov G, Everitt B, Hayward P, David A (1998). Randomised controlled trial of compliance therapy. 18-month follow-up. Br J Psychiatry 172: 413-419.
23. Knottnerus JA, Dinant GJ (1997). Medicine based evidence, a prerequisite for evidence based medicine. BMJ 315:1109-1110.
24. Kwak C (2002). Multinomial logistic regression. Nurs Res 51:404-410.
25. Lehmann P (2005). All about PSY DREAM. Psychiatric Drug Registration, Evaluation and All-inclusive Monitoring. Epidemiol Psichiatr Soc 14:15-21.
26. Lichen Ingram B, Chung RS (1997). Client satisfaction data and quality improvement planning in managed care organizations. Health Care Manage Rev 22:40-52.
27. Magliano L, Fiorillo A, Guarneri M, Marasco C, De RC, Malangone C, Maj M (2004). Prescription of psychotropic drugs to patients with schizophrenia: an Italian national survey. Eur J Clin Pharmacol 60:513-522.
28. Morisky DE, Green LW, Levine DM (1986). Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 24:67-74.
29. National Institute for Clinical Excellence, (2002). Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. London: National Institute for Clinical Excellence.
30. Owen RR, Fischer EP, Kirchner JE, Thrush CR, Williams DK, Cuffel BJ, et al. (2003). Clinical practice variations in prescribing antipsychotics for patients with schizophrenia. Am J Med Qual 18:140-146.
31. Priebe S, Huxley P, Knight S, Evans S (1999). Application and results of the Manchester Short Assessment of Quality of Life (MANSA). Int J Soc Psychiatry 45:7-12.
32. Ruggeri M, Gater R, Bisoffi G, Barbui C, Tansella M (2002). Determinants of subjective quality of life in patients attending community-based mental health services. The South-Verona Outcome Project 5. Acta Psychiatr Scand 105:131-140.
33. Saltini A, Mazzi MA, Del Piccolo L, Zimmermann C (2004). Decisional strategies for the attribution of emotional distress in primary care. Psychol Med 34: 729-739.
34. SPSS Inc., (1999). Answer tree release 2.1. Chicago, Illinois: SPSS Inc.
35. Stahl SM (2004). Focus on antipsychotic polypharmacy: evidence-based prescribing or prescribing-based evidence? Int J Neuropsychopharmacol 7:113-116.
36. STATA Corporation, (2005). STATA statistical software: release 8.2. College Station, Texas: STATA Corp.
37. Thornicroft G, Tansella M (2005). Growing recognition of the importance of service user involvement in mental health service planning and evaluation. Epidemiol Psichiatr Soc 14:1-3.
38. Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, et al. (2002). Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 159:255-262.
39. Ware JE, Sherbourne CD (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30: 473-483.
40. Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R, et al. (1990). SCAN, Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry 47:589-593.